SpyGlass Pharma, Inc. (SGP)
23.87
+3.12
(+15.04%)
USD |
NASDAQ |
Apr 13, 16:00
24.27
+0.40
(+1.68%)
Pre-Market: 08:12
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 795.29M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -- |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.015 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA. |
| URL | http://www.spyglasspharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | May. 29, 2026 (est.) |
| Last Earnings Release | Mar. 26, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA. |
| URL | http://www.spyglasspharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | May. 29, 2026 (est.) |
| Last Earnings Release | Mar. 26, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |